Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 17.87%-10.55M | 35.62%-1.21M | -53.40%-3.68M | 58.60%-1.15M | 22.10%-4.51M | 0.93%-12.85M | 15.80%-1.88M | 43.18%-2.4M | -5.23%-2.78M | -49.46%-5.79M |
Net income from continuing operations | 2.54%-12.98M | -2.44%-3.9M | 10.72%-2.87M | -98.38%-2.94M | 32.13%-3.26M | 34.32%-13.32M | 32.66%-3.81M | 38.32%-3.22M | 71.94%-1.48M | -16.74%-4.81M |
Operating gains losses | -282,800.00%-5.65M | --0 | ---960K | ---- | ---- | --2K | --0 | --0 | --0 | --2K |
Depreciation and amortization | 15.13%723K | 58.46%103K | 23.40%232K | 7.45%202K | -0.53%186K | 1.45%628K | -30.11%65K | -16.07%188K | 44.62%188K | 8.72%187K |
Other non cash items | 867.02%3.69M | -12.24%129K | --0 | 6,596.23%3.55M | -75.76%16K | -1.55%382K | 86.08%147K | 26.09%116K | -48.54%53K | -42.11%66K |
Change In working capital | 388.71%3.22M | 50.57%2.37M | -142.39%-156K | 255.40%2.61M | -15.76%-1.6M | -119.94%-1.12M | -47.95%1.58M | -37.73%368K | -176.09%-1.68M | -511.95%-1.38M |
-Change in receivables | ---571K | -727.47%-571K | --0 | ---- | ---- | --0 | --91K | -1,208.22%-809K | ---- | ---- |
-Change in payables and accrued expense | 227.88%4.7M | 779.17%3.38M | 304.66%966K | 706.00%403K | 98.82%-43K | -156.99%-3.68M | -91.46%384K | -210.28%-472K | -97.70%50K | -459.85%-3.64M |
-Change in other current assets | -90.91%218K | 38.71%-486K | -78.04%369K | 114.44%185K | -94.63%150K | 201.18%2.4M | 73.66%-793K | 1,335.90%1.68M | -2,040.91%-1.28M | 508.06%2.79M |
-Change in other current liabilities | -11.11%-130K | -10.00%-33K | -9.68%-34K | -18.52%-32K | -6.90%-31K | 9.30%-117K | -7.14%-30K | -14.81%-31K | 30.77%-27K | 17.14%-29K |
-Change in other working capital | -454.80%-997K | -95.48%87K | ---1.46M | 280.30%2.05M | -231.42%-1.68M | -82.90%281K | --1.92M | --0 | ---1.14M | ---506K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 17.87%-10.55M | 35.62%-1.21M | -53.40%-3.68M | 58.60%-1.15M | 22.10%-4.51M | 0.93%-12.85M | 15.80%-1.88M | 43.18%-2.4M | -5.23%-2.78M | -49.46%-5.79M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -2,469.38%-4.11M | 252.38%64K | 10.00%-9K | -34,463.64%-3.8M | -275.26%-364K | 78.92%-160K | -281.82%-42K | 69.70%-10K | 92.03%-11K | 83.19%-97K |
Net PPE purchase and sale | 8.75%-146K | 73.81%-11K | -40.00%-14K | -636.36%-81K | 58.76%-40K | 68.57%-160K | 67.19%-42K | 69.70%-10K | 92.03%-11K | 53.81%-97K |
Net intangibles purchase and sale | ---545K | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Net investment purchase and sale | ---3.42M | --75K | --5K | ---3.18M | ---324K | --0 | --0 | --0 | --0 | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -2,469.38%-4.11M | 252.38%64K | 10.00%-9K | -34,463.64%-3.8M | -275.26%-364K | 78.92%-160K | -281.82%-42K | 69.70%-10K | 92.03%-11K | 83.19%-97K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 79.59%6.19M | 0 | 0 | 624.56%6.96M | -257.40%-776K | -74.39%3.45M | -634.34%-529K | -60.81%2.52M | 359.03%961K | -93.24%493K |
Net issuance payments of debt | 56.22%-704K | --0 | --0 | 24.88%-302K | 0.00%-402K | 0.00%-1.61M | 0.00%-402K | 0.00%-402K | 0.00%-402K | 0.00%-402K |
Net common stock issuance | 27.59%6.89M | --0 | --0 | 433.02%7.27M | -141.79%-374K | -65.89%5.4M | -82.65%221K | -57.24%2.92M | 4,296.77%1.36M | -88.37%895K |
Net other financing activities | ---- | ---- | ---- | ---- | ---- | 54.98%-348K | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 79.59%6.19M | --0 | --0 | 624.56%6.96M | -257.40%-776K | -74.39%3.45M | -634.34%-529K | -60.81%2.52M | 359.03%961K | -93.24%493K |
Net cash flow | ||||||||||
Beginning cash position | -52.79%8.55M | -88.89%1.22M | -54.92%4.91M | -77.20%2.9M | -52.79%8.55M | -1.52%18.12M | -45.69%11.01M | -39.77%10.9M | -40.10%12.72M | -1.52%18.12M |
Current changes in cash | 11.37%-8.48M | 53.22%-1.15M | -3,423.42%-3.69M | 210.01%2.01M | -4.74%-5.65M | -3,316.43%-9.57M | -14.26%-2.45M | -94.90%111K | 41.95%-1.83M | -290.10%-5.4M |
End cash Position | -99.11%76K | -99.11%76K | -88.89%1.22M | -54.92%4.91M | -77.20%2.9M | -52.79%8.55M | -52.79%8.55M | -45.69%11.01M | -39.77%10.9M | -40.10%12.72M |
Free cash flow | 13.57%-11.25M | 36.45%-1.22M | -53.34%-3.69M | 36.32%-1.78M | 22.70%-4.55M | 5.24%-13.01M | 14.34%-1.92M | 43.38%-2.41M | -0.40%-2.79M | -32.27%-5.89M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |